Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Islatravir Monotherapy in ART-Naive HIV-1
NCT02217904Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2015
- Primary completion
- May 2017
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of islatravir in human immunodeficiency virus type 1 infection (HIV-1) (7 arms), sponsored by Merck & Co. Primary endpoints: Change From Baseline in Plasma HIV-1 RNA at 168 Hours Post-Dose and Number of Participants With One or More Adverse Events at 21 days. Started Sep 2015; status: completed.
02
Drugs
islatravir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02217904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02217904.